The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a ...

To learn more about the true value of AI and GenAI, pharmaphorum spoke with Sudip Chakraborty, Principal and Head of AI/GenAI ...

In 2018, the EEA accounted for 18% and China made up around 9%, with the massive increase in the latter in a few short years ...

Earlier this month, Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Boston-based Seaport said the money would support a pipeline of improved neuropsychiatric drug candidates led by SPT-300, an ...

Artificial intelligence (AI) is poised to transform Medical Communications. From content creation to data analysis, AI has the potential to greatly enhance productivity and insights generation ...

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

Advances in multi-omics, artificial intelligence (AI), deep learning (DL), ageing biomarkers, precision imaging, ageing clocks, robotics, and smart technologies have enabled researchers to ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...